Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis

Journal of Virology

Volumn 74, Issue 10, 2000, Pages 4816-4823

  Aurisicchio, Luigi ^a   Delmastro, Paola ^a   Salucci, Valentina ^a   Gonzalez Paz, Odalys ^a   Rovere, Patrizia ^a   Ciliberto, Gennaro ^a   La Monica, Nicola ^a   Palombo, Fabio ^a  

^a IRBM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON;

ANIMAL CELL; ARTICLE; GENE EXPRESSION; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; LIVER; NONHUMAN; PRIORITY JOURNAL; TISSUE SPECIFICITY;

ADENOVIRIDAE; ANIMALS; CONCANAVALIN A; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HELPER VIRUSES; HEPATITIS, TOXIC; HEPATITIS, VIRAL, ANIMAL; HUMANS; INTERFERON-ALPHA; LIVER; MICE; MICE, INBRED C57BL; MURINE HEPATITIS VIRUS;

EID: 0033997907     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.10.4816-4823.2000     Document Type: Article

References (42)

1. Armstrong, J. A. 1981. Cytopathic effect inhibition assay for interferon: microculture plate assay. Methods Enzymol. 78:381-387.
2. Ascione, A., M. De Luca, C. Canestrini, G. G. Di Costanzo, G. Raimondo, G. Longo, M. P. Manns, H. L. Tillmann, G. B. Forte, P. Rocco, O. Biceglia, D. Faleo, F. Vinelli, E. M. Cela, L. Amitrano, L. Addario, and T. Gigliotti. 1998. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study. Ital. J. Gastroenterol. Hepatol. 30:517-523.
3. Bahr, G. M., P. R. Pouillart, and L. A. Chedid. 1996. Enhancement in vivo of the antiinflammatory and antitumor activities of type I interferon by association with the synthetic immunomodulator murabutide. J. Interferon Cytokine Res. 16:297-306.
4. Burcin, M. M., G. Schiedner, S. Kochanek, S. Y. Tsai, and B. W. O'Malley. 1999. Adenovirus-mediated regulable target gene expression in vivo. Proc. Natl. Acad. Sci. USA 96:355-360.
5. Cavanaugh, V. J., L. G. Guidotti, and F. V. Chisari. 1998. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J. Virol. 72:2630-2637.
6. Chartier, C., E. Degryse, M. Gantzer. A. Dieterle, A. Pavirani, and M. Mehtali. 1996. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70:4805-4810.
7. Colamonici, O. R., B. Porterfield, P. Domanski, S. Constantinescu, and L. M. Pfeffer. 1994. Complementation of the interferon alpha response in resistant cells by expression of the cloned subunit of the interferon alpha receptor. A central role of this subunit in interferon alpha signaling. J. Biol. Chem. 269:9598-9602.
8. David, M. 1995. Transcription factors in interferon signaling. Pharmacol. Ther. 65:149-161.
9. Davis, G. L., R. Esteban-Mur, V. Rustgi, J. Hoefs, S. C. Gordon, C. Trepo, M. L. Shiffman, S. Zeuzem, A. Craxi, M. H. Ling, and J. Albrecht. 1998. Interferon alfa-2b alone or in combination with rihavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339:1493-1499.
10. Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverman. 1998. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc. Natl. Acad. Sci. USA 95:15623-15628.
11. Ding, J. W., Q. Ning, M. F. Liu, A. Lai, J. Leibowitz, K. M. Peltekian, E. H. Cole, L. S. Fung, C. Holloway, P. A. Marsden, H. Yeger, M. J. Phillips, and G. A. Levy. 1997. Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel fgl2 prothrombinase. J. Virol. 71:9223-9230. (Erratum, 72:3504, 1998.)
12. Domanski, P., and O. R. Colamonici. 1996. The type-1 interferon receptor. The long and short of it. Cytokine Growth Factor Rev. 7:143-151.
13. Eto, T., and H. Takahashi. 1999. Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. Nat. Med. 5:577-581.
14. Guidotti, L. G., R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829.
15. Heremans, H., A. Billiau, and P. De Somer. 1980. Interferon in experimental viral infections in mice: tissue interferon levels resulting from the virus infection and from exogenous interferon therapy. Infect. Immun. 30:513-522.
16. Heremans, H., R. Dijkmans, H. Sobis, F. Vandekerckhove, and A. Billiau. 1987. Regulation by interferons of the local inflammatory response to bacterial lipopolysaccharide. J. Immunol. 138:4175-4179.
17. Huard, J., H. Lochmuller, G. Acsadi, A. Jani, B. Massie, and G. Karpati. 1995. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2:107-115.
18. Isaacs, A., and J. Lindenmann. 1957. I. Virus interference. Proc. R. Soc. Lond. 147:258-267.
19. Kato, Y., Y. Noda, M. Unoura, N. Tanaka, K. Kobayashi, N. Hattori, K. Hatano, and S. Kobayashi. 1986. Effect of exogenous mouse interferon on murine fulminant hepatitis induced by mouse hepatitis virus type 2. Dig. Dis. Sci. 31:177-180.
20. Maione, D., M. Wiznerowicz, P. Delmastro, R. Cortese, G. Ciliberto, N. La Monica, and R. Savino. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum. Gene Ther. in press.
21. Makino, S., C. K. Shieh, L. H. Soe, S. C. Baker, and M. M. Lai. 1988. Primary structure and translation of a defective interfering RNA of murine corona-virus. Virology 166:550-560.
22. Minagawa, H., A. Takenaka, S. Mohri, and R. Mori. 1987. Protective effect of recombinant murine interferon beta against mouse hepatitis virus infection. Antiviral Res. 8:85-95.
23. Mizuhara, H., M. Kuno, N. Seki, W. G. Yu, M. Yamaoka, M. Yamashita, T. Ogawa, K. Kaneda, T. Fujii, H. Senoh, and H. Fujiwara. 1998 Strain difference in the induction of T-cell activation-associated, interferon gamma-dependent hepatic injury in mice. Hepatology 27:513-519.
24. Morsy, M. A., M. Gu, S. Motzel, J. Zhao, J. Lin, Q. Su, H. Allen, L. Franlin, R. J. Parks, F. L. Graham, S. Kochanek, A. J. Bett, and C. T. Caskey. 1998. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. USA 95:7866-7871.
25. Parks, R. J., L. Chen, M. Anton, U. Sankar, M. A. Rudnicki, and F. L. Graham. 1996. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA 93:13565-13570.
26. Polyak, S. J., D. M. Paschal, S. McArdle, M. J. Gale, Jr., D. Moradpour, and D. R. Gretch. 1999. Characterization of the effects of hepatitis C virus nonstructural 5A protein expression in human cell lines and on interferon-sensitive virus replication. Hepatology 29:1262-1271.
27. Qian, X., U. Samadani, A. Porcella, and R. H. Costa. 1995. Decreased expression of hepatocyte nuclear factor 3 alpha during the acute-phase response influences transthyretin gene transcription. Mol. Cell. Biol. 15: 1364-1376.
28. Qin, X. Q., N. Tao, A. Dergay, P. Moy, S. Fawell, A. Davis, J. M. Wilson, and J. Barsoum. 1998. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc. Natl. Acad. Sci. USA 95:14411-14416.
29. Recchia, A., R. J. Parks, S. Lamartina, C. Toniatti, L. Pieroni, F. Palombo, G. Ciliberto, F. L. Graham, R. Cortese, N. La Monica, and S. Colloca. 1999. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proc. Natl. Acad. Sci. USA 96:2615-2620.
30. Reichard, O., G. Norkrans, A. Fryden, J. H. Braconier, A. Sonnerborg, and O. Weiland. 1998. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without rihavirin for chronic hepatitis C. The Swedish Study Group. Lancet 351:83-87.
31. Rice, A. P., R. Duncan, J. W. Hershey, and I. M. Kerr. 1985. Double-stranded RNA-dependent protein kinase and 2-5A system are both activated in interferon-treated, encephalomyocarditis virus-infected HeLa cells. J. Virol. 54:894-898.
32. Roggendorf, M., and T. K. Tolle. 1995. The woodchuck: an animal model for hepatitis B virus infection in man. Intervirology 38:100-112.
33. Schiedner, G., N. Morral, R. J. Parks, Y. Wu, S. C. Koopmans, C. Langston, F. L. Graham, A. L. Beaudet, and S. Kochanek. 1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 18:180-183. (Erratum, 18:298.)
34. Stemmer, W. P., A. Crameri, K. D. Ha, T. M. Brennan, and H. L. Heyneker. 1995. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene 164:49-53.
35. Tan, S. L., H. Nakao, Y. He, S. Vijaysri, P. Neddermann, B. L. Jacobs, B. J. Mayer, and M. G. Katze. 1999. NS5A. a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc. Natl. Acad. Sci. USA 96:5533-5538.
36. Taylor, D. R., S. T. Shi, P. R. Romano, G. N. Barber, and M. M. Lai. 1999. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285:107-110.
37. Tripathy, S. K., H. B. Black, E. Goldwasser, and J. M. Leiden. 1996. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nat. Med. 2:545-550.
38. Vilcek, J., and C. S. Ganes. 1996. Interferon and other cytokines, p. 375-399. In B. N. Fields. D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
39. Wermers, G. W., H. Band, and E. J. Yunis. 1998. Role of the HLA system in antigen recognition and disease. Raven Press, New York, N.Y.
40. Wills, R. J. 1990. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet. 19:390-399.
41. Yang, Y., F. A. Nunes, K. Berencsi, E. E. Furth, E. Gonczol, and J. M. Wilson. 1994. Cellular immunity to viral antigens limits E1-deleted adeno-viruses for gene therapy. Proc. Natl. Acad. Sci. USA 91:4407-4411.
42. Yeow, W. S., C. M. Lawson, and M. W. Beilharz. 1998. Antiviral activities of individual murine IFN-alpha subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. J. Immunol. 160: 2932-2939.